Wire · founder news, decoded · opportunities
Trial paper is retracted as FDA keeps scrutiny on controversial vasculitis drug | The BMJ
A pivotal vasculitis drug trial (avacopan/Tavneos) has been retracted by NEJM after FDA found evidence of data manipulation; the EMA is revoking its marketing authorisation, creating major regulatory uncertainty for the drug's continued approval.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
Founders in clinical-stage biotech must understand that data integrity breaches trigger cascading regulatory failures across territories; trial retractions and approvals revocation signal tightened FDA/EMA scrutiny on trial conduct and patient safety claims.
Read the full story at bmj.com →
Topics: Digital Health · data-integrity · drug-approval · fda-scrutiny · vasculitis · clinical-trials · regulatory-risk